Furthermore, DOAC overdoses in renal insufficiency, less frequent pharmacokinetic DDIs and contraindications with potent cytochrome P450 system 3A4 (CYP3A4) or p-glycoprotein (p-GP) inhibitors or liver dysfunction required adjustments. The gene discussed is CYP3A4; the disease is Decreased liver function.